The ARASEC study prospectively examined darolutamide plus ADT in US men with mHSPC, but used a historical control group receiving ADT monotherapy from the phase 3 CHAARTED trial for matching and ...

U.S. study supports findings from a global trial using an external control arm ...

Phase II ARASEC Data Further Supports the Efficacy and Safety of NUBEQA® (darolutamide) Plus ADT in Patients with mCSPC ...

Prostate cancer is the most common malignancy among men, with over 160,000 new cases diagnosed annually in the United States. Although advances in surgery, radiotherapy, and hormone therapy have ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Rana R. McKay, MD: ...

SAN FRANCISCO -- Men with high-risk localized prostate cancer lived significantly longer with dose-escalated radiation therapy (RT) plus long-term androgen deprivation therapy (ADT), according to long ...

Alicia Morgans, MD, MPH, discusses androgen deprivation therapy and its role in treating prostate cancer. Alicia Morgans, M.D., MPH: Androgen deprivation therapy, sometimes called ADT or hormonal ...

Metastasis-directed therapy added to ADT helps slow the progression of metastatic prostate cancer, a phase 2 trial finds. The addition of metastasis-directed therapy (MDT) to androgen deprivation ...

Many common medications may cause or worsen heart failure. A recent cohort study evaluated the risk of developing Alzheimer dementia after ADT in 16,888 men with prostate cancer, 14.2% of whom were ...

Overall, 30 months of adjuvant androgen deprivation therapy (ADT) did not improve biochemical control and other survival endpoints compared with just 6 months of ADT in men with high-risk localized ...

Metastatic prostate cancer is cancer that began in the prostate but has spread to other parts of the body. There's no cure, but there are a number of effective treatments you can discuss with a ...